---
title: "EVIDENT cRCT protocol: Introducing the NPOC MiniDock MTB test to improve TB diagnosis in Indonesia"
id: "medrxiv-1-evaluation-and-demonstration-of-a-new-tuberculosis-diagnostic-tool-for"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-1-evaluation-and-demonstration-of-a-new-tuberculosis-diagnostic-tool-for"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.12.26360245v1?rss=1"
published_at: "2026-08-13T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# EVIDENT cRCT protocol: Introducing the NPOC MiniDock MTB test to improve TB diagnosis in Indonesia
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-1-evaluation-and-demonstration-of-a-new-tuberculosis-diagnostic-tool-for
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.12.26360245v1?rss=1)
- **Published At:** 2026-08-13T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This article is the study protocol for the EVIDENT **cluster randomised controlled trial (cRCT)** evaluating a multi-component intervention to improve **tuberculosis (TB)** diagnosis and notification in Indonesia. - The trial is pragmatic and will be conducted in Bandung District, with 40 community health centre (CHC) areas randomised 1:1 to intervention or control arms. - The central clinical innovation is the first-in-class near-point-of-care (NPOC) **MiniDock MTB test** (Guangzhou Pluslife Biotech, China), to be used on **sputum**, **tongue swabs**, or both specimen types. - The intervention comprises four components: (a) introduction of the NPOC test in health facilities and community settings, (b) optimisation of clinical algorithms to incorporate the new test, (c) a promotional package to increase patient attendance and test use, and (d) TB household contact investigation conducted by community health volunteers that includes the new test. - Control areas will continue standard of care; both arms will receive TB notification refresher training before intervention roll-out. - The primary outcome is the number of TB cases diagnosed and notified by health care facilities per population attending them; measurement will use routine data abstracted for 12 months after intervention roll-out and compared with 12 months before any trial activities. - The trial aims to assess whether introducing an NPOC molecular test plus supporting programmatic measures increases TB diagnosis and notification, potentially informing policy for Indonesia and other high-burden countries. - The protocol reports prior ethical approvals: Universitas Padjadjaran Research Ethics Committee initial approval (Number 467/UN6.KEP/EC/2025) on May 21, 2025, and a protocol amendment approval (Number 7/UN6.KEP/EC/2026) on February 5, 2026. - The study is registered on ClinicalTrials.gov (NCT07293455). The authors report no competing interests. - No datasets were generated or analysed for this protocol; data will be made available after study completion. - As this is a preprint, the study has not yet been peer reviewed and results are not yet available to guide clinical practice.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=rblaZ.esz3GuI4cyKzFGNyikN2NhwCQRvBCYLiS.rnw-1786641652.8905163-1.2.1.1-STgAxx_yqgVXg2CL09Gpisk4fZUxAnKC6gUNpOEIzzxIJRDvAcaIr12Vq7He2AjH) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.12.26360245v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Evaluation and demonstration of a new tuberculosis diagnostic tool for Indonesia: Study protocol of the EVIDENT cluster randomised controlled trial [ View ORCID Profile](http://orcid.org/0000-0003-0829-6320)Nur Afifah, [ View ORCID Profile](http://orcid.org/0000-0002-3817-4589)Raspati Cundarani Koesoemadinata, Edwin Ardiansyah, [ View ORCID Profile](http://orcid.org/0000-0002-7566-8457)Kurnia Wahyudi, Bony Wiem Lestari, Reinout van Crevel, [ View ORCID Profile](http://orcid.org/0000-0003-3525-2294)Stephen Graham, Susan Margaret McAllister, Katrina Sharples, Philip Campbell Hill, [ View ORCID Profile](http://orcid.org/0000-0003-3745-8229)Bachti Alisjahbana doi: https://doi.org/10.64898/2026.08.12.26360245 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Nur Afifah 1 Universitas Padjadjaran; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nur%2BAfifah%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Afifah%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANur%2BAfifah%2B) * [ORCID record for Nur Afifah](http://orcid.org/0000-0003-0829-6320 "Open in new tab") Raspati Cundarani Koesoemadinata 2 Universitas Pendidikan Indonesia; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Raspati%2B%2BCundarani%2BKoesoemadinata%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Koesoemadinata%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARaspati%2B%2BCundarani%2BKoesoemadinata%2B) * [ORCID record for Raspati Cundarani Koesoemadinata](http://orcid.org/0000-0002-3817-4589 "Open in new tab") Edwin Ardiansyah 1 Universitas Padjadjaran; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Edwin%2BArdiansyah%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ardiansyah%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEdwin%2BArdiansyah%2B) Kurnia Wahyudi 1 Universitas Padjadjaran; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kurnia%2BWahyudi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Wahyudi%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKurnia%2BWahyudi%2B) * [ORCID record for Kurnia Wahyudi](http://orcid.org/0000-0002-7566-8457 "Open in new tab") Bony Wiem Lestari 1 Universitas Padjadjaran; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Bony%2B%2BWiem%2BLestari%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lestari%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABony%2B%2BWiem%2BLestari%2B) Reinout van Crevel 3 Radboudumc; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Reinout%2Bvan%2BCrevel%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=van%20Crevel%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AReinout%2Bvan%2BCrevel%2B) Stephen Graham 4 University of Melbourne; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Stephen%2BGraham%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Graham%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AStephen%2BGraham%2B) * [ORCID record for Stephen Graham](http://orcid.org/0000-0003-3525-2294 "Open in new tab") Susan Margaret McAllister 5 University of Otago * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Susan%2B%2BMargaret%2BMcAllister%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=McAllister%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASusan%2B%2BMargaret%2BMcAllister%2B) Katrina Sharples 5 University of Otago * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Katrina%2BSharples%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sharples%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKatrina%2BSharples%2B) Philip Campbell Hill 5 University of Otago * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Philip%2B%2BCampbell%2BHill%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hill%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APhilip%2B%2BCampbell%2BHill%2B) Bachti Alisjahbana 1 Universitas Padjadjaran; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Bachti%2BAlisjahbana%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Alisjahbana%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABachti%2BAlisjahbana%2B) * [ORCID record for Bachti Alisjahbana](http://orcid.org/0000-0003-3745-8229 "Open in new tab") * For correspondence: b.alisjahbana@unpad.ac.id * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.12.26360245v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1277947/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.12.26360245v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1277947/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.12.26360245v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1277947/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.12.26360245v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1277947/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.12.26360245v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1277947/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Introduction: Most people with tuberculosis (TB) reside in countries with limited resources for prompt TB diagnosis, resulting in diagnosis and treatment delays and ongoing community transmission. Current TB diagnostics rely on sputum, while some people with presumptive TB cannot produce adequate sample. A new generation near-point-of-care (NPOC) tests using sputum or tongue swabs may provide more accessible TB diagnosis. Methods: In this pragmatic cluster randomised controlled trial (cRCT) in Indonesia, a multi-component public health intervention will include: (a) introduction of NPOC MiniDock MTB test (Guangzhou Pluslife Biotech, China) on sputum, tongue swab, or both specimens, (b) optimisation of clinical algorithms incorporating the new test, (c) a promotional package to encourage patient attendance and test utilisation, and (d) TB household contact investigation, including the new test, by community health volunteers. We will randomly stratify 40 community health centre (CHC) areas into intervention and control arms (1:1) in Bandung District. The intervention will be administered in healthcare facilities (HCFs) and in the community of the intervention areas. The control areas will continue standard of care with no intervention, except TB notification refresher training, which will be delivered in both areas before intervention roll-out. The primary outcome is the number of TB cases diagnosed and notified by HCFs per population attending them. It will be measured by abstracting data on TB case notification and the number of HCF attendees over 12 months following completion of the intervention roll-out, compared to 12 months preceding any trial activities. Discussion: This trial will evaluate the effect of an intervention package incorporating the first-in-class NPOC on TB diagnosis and notification. The trial results will inform policy to improve TB diagnostic efforts in Indonesia and other high burden TB countries. Trial Registration: ClinicalTrials.Gov, [NCT07293455](https://www.medrxiv.org/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT07293455&atom=%2Fmedrxiv%2Fearly%2F2026%2F08%2F13%2F2026.08.12.26360245.atom). ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial ClinicalTrials.Gov, [NCT07293455](https://www.medrxiv.org/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT07293455&atom=%2Fmedrxiv%2Fearly%2F2026%2F08%2F13%2F2026.08.12.26360245.atom). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study has received initial ethical approval from the Research Ethics Committee, Universitas Padjadjaran Bandung (Number 467/UN6.KEP/EC/2025) on May 21, 2025. A protocol amendment was reviewed and approved by the same committee (Number 7/UN6.KEP/EC/2026) on February 5, 2026. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.12.26360245v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.12.26360241v1 "Diffusion kurtosis imaging \(gen\)omics unravels mechanisms of cerebral small vessel disease")[Next ](https://www.medrxiv.org/content/10.64898/2026.05.19.26353597v2 "Data Assimilation Substitutes for Biological Complexity in Hybrid Influenza Forecasting Models") Posted August 13, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.12.26360245v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/13/2026.08.12.26360245.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.12.26360245v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/13/2026.08.12.26360245.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Evaluation and demonstration of a new tuberculosis diagnostic tool for Indonesia: Study protocol of the EVIDENT cluster randomised controlled trial Nur Afifah, Raspati Cundarani Koesoemadinata, Edwin Ardiansyah, Kurnia Wahyudi, Bony Wiem Lestari, Reinout van Crevel, Stephen Graham, Susan Margaret McAllister, Katrina Sharples, Philip Campbell Hill, Bachti Alisjahbana medRxiv 2026.08.12.26360245; doi: https://doi.org/10.64898/2026.08.12.26360245 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.12.26360245v1%26text%3DEvaluation%2520and%2520demonstration%2520of%2520a%2520new%2520tuberculosis%2520diagnostic%2520tool%2520for%2520Indonesia%253A%2520Study%2520protocol%2520of%2520the%2520EVIDENT%2520cluster%2520randomised%2520controlled%2520trial "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.12.26360245v1%26t%3DEvaluation%2520and%2520demonstration%2520of%2520a%2520new%2520tuberculosis%2520diagnostic%2520tool%2520for%2520Indonesia%253A%2520Study%2520protocol%2520of%2520the%2520EVIDENT%2520cluster%2520randomised%2520controlled%2520trial "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.12.26360245v1%26title%3DEvaluation%2520and%2520demonstration%2520of%2520a%2520new%2520tuberculosis%2520diagnostic%2520tool%2520for%2520Indonesia%253A%2520Study%2520protocol%2520of%2520the%2520EVIDENT%2520cluster%2520randomised%2520controlled%2520trial%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.12.26360245v1%26title%3DEvaluation%2520and%2520demonstration%2520of%2520a%2520new%2520tuberculosis%2520diagnostic%2520tool%2520for%2520Indonesia%253A%2520Study%2520protocol%2520of%2520the%2520EVIDENT%2520cluster%2520randomised%2520controlled%2520trial "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.12.26360245) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.12.26360245v1&count=horizontal&via=&text=Evaluation%20and%20demonstration%20of%20a%20new%20tuberculosis%20diagnostic%20tool%20for%20Indonesia%3A%20Study%20protocol%20of%20the%20EVIDENT%20cluster%20randomised%20controlled%20trial&counturl=www.medrxiv.org/content/10.64898/2026.08.12.26360245v1 "Tweet This") ## Subject Area * [Public and Global Health ](https://www.medrxiv.org/collection/public-and-global-health) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (604) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (891) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (322) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4714) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (469) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (403) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (633) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1601) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15711) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1187) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6917) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (722) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1041) * [Health Informatic
## Related Clinical Research

- [Impact of Post‑TB Consequences on Effectiveness and Cost‑effectiveness of Immigrant TB Prevention](https://medichelpline.com/clinical-feed/cdc-emerging-infectious-diseases-journal-0-posttuberculosis-consequences-on-tuberculosis-prevention-effectiveness-and-cost.md)
- [MDA5 senses disrupted RNA processing: cellular RNAs drive activation during viral infection](https://medichelpline.com/clinical-feed/nature-immunology-2-loss-of-cellular-rna-homeostasis-contributes-to-mda5-activation-during-virus.md)
- [Theranostics for Infectious Lung Diseases: Biotechnology and Nanotechnology for Precision Care](https://medichelpline.com/clinical-feed/pubmed-42549821.md) (DOI: 10.1080/14737159.2026.2714060)
- [Tuberculosis Risk After TB Preventive Therapy in People with HIV Initiating ART](https://medichelpline.com/clinical-feed/cdc-emerging-infectious-diseases-journal-5-tuberculosis-after-preventive-therapy-in-persons-living-with-hiv-initiating.md)
- [DAG-HEART: DAG-Guided Transfer Learning to Improve Equity-Aware Breast Cancer Prediction](https://medichelpline.com/clinical-feed/biorxiv-0-dag-heart-directed-acyclic-graph-guided-health-equity-aware-representation.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.